Deepcell Launches AI-Powered Single Cell Analysis Platform to Accelerate Cell Biology Discovery and Catalyze Field of Morpholomics

Thursday, May 18, 2023

Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced the launch of the REM-I Platform, a high-dimensional cell morphology analysis and sorting platform which comprises the REM-I benchtop instrument, Human Foundation Model, and Axon data suite. By bringing together single cell imaging, sorting, and high-dimensional analysis, the REM-I Platform will catalyze new methods of discovery in a wide range of fields including cancer biology, developmental biology, stem cell biology, gene therapy and functional screening, among others. Deepcell’s leaders will present data on the company’s AI-based morphology profiling solutions, which leverage the company’s proprietary deep learning and computer vision model, during three scientific podium presentations at CYTO 2023 in Montreal, Quebec, May 20-24, 2023.

“Deepcell’s approach to bringing artificial intelligence into cellular analysis will revolutionize biological research, ushering in a new era of discovery,” Maddison Masaeli, PhD, cofounder and chief executive officer at Deepcell. “We empower our customers to rapidly transform biological research by applying the latest advances in AI to morphology, which is the bedrock of cell biology.”

Cell morphology was one of the first ways cells were studied since the advent of the microscope. Despite recent advancements in microscopy and flow cytometry, existing tools for cellular quantification and characterization have left the field of cell biology hypothesis bounded and reliant on human interpretation, until now. With the new generation of AI and machine learning models like Deepcell’s Human Foundation Model, cell morphology can finally join other high-dimensional, single cell analysis methods and enable researchers to realize the full potential of the morpholome.

“In the launch of the REM-I Platform we are witnessing the realization of years of first-principle thinking about the future of cell biology— a future liberated from the constraints of prior knowledge,” said Euan Ashley, MD, PhD, scientific cofounder of Deepcell, associate dean in the Stanford University School of Medicine and professor at Stanford University. “With the help of sophisticated artificial intelligence models, we can surpass the limits of what our eyes can see and peer ever more deeply into the biology of individual cells. I can’t wait to see what the scientific community does with this powerful new tool.”



Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare CNO SummitHealthcare CMO Summit